西马鲁肽对离体人心室心肌的心脏保护作用

IF 16.9 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

European Journal of Heart Failure Pub Date : 2025-03-19 DOI:10.1002/ejhf.3644

Thomas Krammer, Maria J. Baier, Philipp Hegner, Tilman Zschiedrich, David Lukas, Matthias Wolf, Christian Le Phu, Vanessa Lutz, Katja Evert, Kostiantyn Kozakov, Jing Li, Andreas Holzamer, Lars S. Maier, Zdenek Provaznik, Donald M. Bers, Stefan Wagner, Julian Mustroph

{"title":"西马鲁肽对离体人心室心肌的心脏保护作用","authors":"Thomas Krammer, Maria J. Baier, Philipp Hegner, Tilman Zschiedrich, David Lukas, Matthias Wolf, Christian Le Phu, Vanessa Lutz, Katja Evert, Kostiantyn Kozakov, Jing Li, Andreas Holzamer, Lars S. Maier, Zdenek Provaznik, Donald M. Bers, Stefan Wagner, Julian Mustroph","doi":"10.1002/ejhf.3644","DOIUrl":null,"url":null,"abstract":"Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promising effects in reducing cardiovascular events in patients with obesity and heart failure (HF) with preserved ejection fraction (HFpEF) irrespective of concomitant diabetes. However, the exact mechanisms underlying its cardioprotective actions remain unclear. Our study investigates the direct effects of semaglutide on human cardiomyocytes, focusing on calcium (Ca) and sodium (Na) handling and its potential to improve myocardial contractility.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"45 1","pages":""},"PeriodicalIF":16.9000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cardioprotective effects of semaglutide on isolated human ventricular myocardium\",\"authors\":\"Thomas Krammer, Maria J. Baier, Philipp Hegner, Tilman Zschiedrich, David Lukas, Matthias Wolf, Christian Le Phu, Vanessa Lutz, Katja Evert, Kostiantyn Kozakov, Jing Li, Andreas Holzamer, Lars S. Maier, Zdenek Provaznik, Donald M. Bers, Stefan Wagner, Julian Mustroph\",\"doi\":\"10.1002/ejhf.3644\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promising effects in reducing cardiovascular events in patients with obesity and heart failure (HF) with preserved ejection fraction (HFpEF) irrespective of concomitant diabetes. However, the exact mechanisms underlying its cardioprotective actions remain unclear. Our study investigates the direct effects of semaglutide on human cardiomyocytes, focusing on calcium (Ca) and sodium (Na) handling and its potential to improve myocardial contractility.\",\"PeriodicalId\":164,\"journal\":{\"name\":\"European Journal of Heart Failure\",\"volume\":\"45 1\",\"pages\":\"\"},\"PeriodicalIF\":16.9000,\"publicationDate\":\"2025-03-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Heart Failure\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ejhf.3644\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ejhf.3644","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

Semaglutide是一种胰高血糖素样肽-1 （GLP-1）受体激动剂，在具有保留射血分数（HFpEF）的肥胖和心力衰竭（HF）患者中显示出有希望的减少心血管事件的效果，而不管是否伴有糖尿病。然而，其心脏保护作用的确切机制尚不清楚。我们的研究探讨了西马鲁肽对人心肌细胞的直接影响，重点是钙（Ca）和钠（Na）处理及其改善心肌收缩性的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Cardioprotective effects of semaglutide on isolated human ventricular myocardium

查看原文本刊更多论文

Cardioprotective effects of semaglutide on isolated human ventricular myocardium

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promising effects in reducing cardiovascular events in patients with obesity and heart failure (HF) with preserved ejection fraction (HFpEF) irrespective of concomitant diabetes. However, the exact mechanisms underlying its cardioprotective actions remain unclear. Our study investigates the direct effects of semaglutide on human cardiomyocytes, focusing on calcium (Ca) and sodium (Na) handling and its potential to improve myocardial contractility.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Journal of Heart Failure 医学-心血管系统

CiteScore

27.30

自引率

11.50%

发文量

365

审稿时长

1 months

期刊介绍： European Journal of Heart Failure is an international journal dedicated to advancing knowledge in the field of heart failure management. The journal publishes reviews and editorials aimed at improving understanding, prevention, investigation, and treatment of heart failure. It covers various disciplines such as molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, clinical sciences, social sciences, and population sciences. The journal welcomes submissions of manuscripts on basic, clinical, and population sciences, as well as original contributions on nursing, care of the elderly, primary care, health economics, and other related specialist fields. It is published monthly and has a readership that includes cardiologists, emergency room physicians, intensivists, internists, general physicians, cardiac nurses, diabetologists, epidemiologists, basic scientists focusing on cardiovascular research, and those working in rehabilitation. The journal is abstracted and indexed in various databases such as Academic Search, Embase, MEDLINE/PubMed, and Science Citation Index.